Evaluation of two year treatment outcome and limited impact of arginine restriction in a patient with GAMT deficiency

Abstract

A 4-year-old female with history of developmental regression and autistic features was diagnosed with guanidinoacetate methyltransferase deficiency at age 21months. Upon treatment, she showed improvements in her developmental milestones, sensorial-neural hearing loss and brain atrophy on cranial-MRI. The creatine/choline ratio increased 82% in basal ganglia and 88% in white matter on cranial MR-spectroscopy. The CSF guanidinoacetate decreased 80% after six months of ornithine and creatine supplementation and an additional 8% after 18months of additional arginine restricted diet. We report the most favorable clinical and biochemical outcome on treatment in our patient.